Imunon, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Imunon, Inc. (IMNN) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$9.78 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-15.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-15
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$9.78M.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $9.98M, a 13.96% increase year-over-year.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$9.38M.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $10.47M.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $1.91M, a 78.35% decline from fiscal 2017.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $8.82M.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$6.64M.
- Imunon, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$3.42M, a 149.10% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|---|
| 2019-03-31 | -$9.78M 10-Q · filed 2019-05-15 | $204.29K derived: sum of 2 quarters · filed 2019-05-15 | -$9.18M derived: sum of 3 quarters · filed 2019-05-15 | $1.29M derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2018-12-31 | $9.98M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $599.85K derived: sum of 2 quarters · filed 2019-03-29 | $11.07M derived: sum of 3 quarters · filed 2019-03-29 | $1.91M 10-K · filed 2019-03-29 | ||
| 2018-09-30 | -$9.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $1.09M derived: sum of 2 quarters · filed 2018-11-14 | -$8.07M 10-Q · filed 2018-11-14 | $686.29K derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2018-06-30 | $10.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $1.31M 10-Q · filed 2018-08-14 | $10.07M derived: sum of 3 quarters · filed 2019-05-15 | $9.12M derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2018-03-31 | -$9.16M 10-Q · filed 2019-05-15 | -$399.70K derived: sum of 2 quarters · filed 2019-05-15 | -$1.34M derived: sum of 3 quarters · filed 2019-05-15 | -$2.18M derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $7.82M derived: sum of 2 quarters · filed 2019-03-29 | $6.97M derived: sum of 3 quarters · filed 2019-03-29 | $8.82M 10-K · filed 2019-03-29 | ||
| 2017-09-30 | -$944.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$1.78M derived: sum of 2 quarters · filed 2018-11-14 | $60.85K 10-Q · filed 2018-11-14 | -$1.50M derived: sum of 4 quarters · filed 2018-11-14 | ||
| 2017-06-30 | -$840.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $1.00M 10-Q · filed 2018-08-14 | -$555.18K derived: sum of 3 quarters · filed 2018-08-14 | -$8.68M derived: sum of 4 quarters · filed 2018-08-14 | ||
| 2017-03-31 | $1.85M 10-Q · filed 2018-05-11 | $285.35K derived: sum of 2 quarters · filed 2018-05-11 | -$7.84M derived: sum of 3 quarters · filed 2018-05-11 | -$9.84M derived: sum of 4 quarters · filed 2018-05-11 | ||
| 2016-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-27 | -$9.68M derived: sum of 2 quarters · filed 2018-03-27 | -$11.69M derived: sum of 3 quarters · filed 2018-03-27 | -$6.64M 10-K · filed 2018-03-27 | ||
| 2016-09-30 | -$8.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$10.13M derived: sum of 2 quarters · filed 2017-11-14 | -$5.08M 10-Q · filed 2017-11-14 | -$3.39M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $3.04M 10-Q · filed 2017-08-14 | $4.73M derived: sum of 3 quarters · filed 2017-08-14 | $356.80K derived: sum of 4 quarters · filed 2017-08-14 | ||
| 2016-03-31 | $5.05M 10-Q · filed 2017-05-12 | $6.74M derived: sum of 2 quarters · filed 2017-05-12 | $2.36M derived: sum of 3 quarters · filed 2017-05-12 | $6.70M derived: sum of 4 quarters · filed 2017-05-12 | ||
| 2015-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | -$2.69M derived: sum of 2 quarters · filed 2017-03-24 | $1.65M derived: sum of 3 quarters · filed 2017-03-24 | -$3.42M 10-K · filed 2017-03-24 | ||
| 2015-09-30 | -$4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$39.41K derived: sum of 2 quarters · filed 2016-11-10 | -$5.11M 10-Q · filed 2016-11-10 | $3.02M derived: sum of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$735.89K 10-Q · filed 2016-08-15 | $7.39M derived: sum of 3 quarters · filed 2016-08-15 | $2.35M derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | -$5.07M 10-Q · filed 2016-05-16 | $3.06M derived: sum of 2 quarters · filed 2016-05-16 | -$1.98M derived: sum of 3 quarters · filed 2016-05-16 | $3.01M derived: sum of 4 quarters · filed 2016-05-16 | ||
| 2014-12-31 | $8.13M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $3.09M derived: sum of 2 quarters · filed 2016-03-30 | $8.08M derived: sum of 3 quarters · filed 2016-03-30 | $6.97M 10-K · filed 2016-03-30 | ||
| 2014-09-30 | -$5.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$47.91K derived: sum of 2 quarters · filed 2015-11-05 | -$1.16M 10-Q · filed 2015-11-05 | -$8.61M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-06-30 | $4.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $3.88M 10-Q · filed 2015-08-10 | -$3.57M derived: sum of 3 quarters · filed 2016-03-30 | $3.58M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2014-03-31 | -$1.11M 10-Q · filed 2015-05-11 | -$8.56M derived: sum of 2 quarters · filed 2016-03-30 | -$1.41M derived: sum of 3 quarters · filed 2016-03-30 | -$5.01M derived: sum of 4 quarters · filed 2016-03-30 | ||
| 2013-12-31 | -$7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$302.02K derived: sum of 2 quarters · filed 2016-03-30 | -$3.90M derived: sum of 3 quarters · filed 2016-03-30 | -$9.27M 10-K · filed 2016-03-30 | ||
| 2013-09-30 | $7.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $3.55M derived: sum of 2 quarters · filed 2014-11-10 | -$1.82M 10-Q · filed 2014-11-10 | $4.85M derived: sum of 4 quarters · filed 2015-03-12 | ||
| 2013-06-30 | -$3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$8.97M 10-Q · filed 2014-08-07 | -$8.97M 10-Q · filed 2013-08-08 | -$2.30M derived: sum of 3 quarters · filed 2015-03-12 | -$5.69M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-03-31 | -$5.38M 10-Q · filed 2014-05-08 | $5.38M 10-Q · filed 2013-05-09 | $1.30M derived: sum of 2 quarters · filed 2015-03-12 | -$2.09M derived: sum of 3 quarters · filed 2015-03-12 | $494.22K derived: sum of 4 quarters · filed 2015-03-12 | |
| 2012-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $3.28M derived: sum of 2 quarters · filed 2015-03-12 | $5.87M derived: sum of 3 quarters · filed 2015-03-12 | -$5.15M 10-K · filed 2015-03-12 | ||
| 2012-09-30 | -$3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$803.74K derived: sum of 2 quarters · filed 2013-11-12 | -$11.83M 10-Q · filed 2013-11-12 | -$2.81M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$8.44M 10-Q · filed 2013-08-08 | $575.22K derived: sum of 3 quarters · filed 2014-03-13 | $6.33M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-03-31 | -$11.02M 10-Q · filed 2013-05-09 | -$2.01M derived: sum of 2 quarters · filed 2014-03-13 | $3.74M derived: sum of 3 quarters · filed 2014-03-13 | $7.16M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2011-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $14.77M derived: sum of 2 quarters · filed 2014-03-13 | $18.18M derived: sum of 3 quarters · filed 2014-03-13 | $19.01M 10-K · filed 2014-03-13 | ||
| 2011-09-30 | $5.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $9.17M derived: sum of 2 quarters · filed 2012-11-09 | $9.99M 10-Q · filed 2012-11-09 | $9.31M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $4.24M 10-Q · filed 2012-08-14 | $3.56M derived: sum of 3 quarters · filed 2013-03-18 | $2.63M derived: sum of 4 quarters · filed 2013-03-18 | ||
| 2011-03-31 | $825.62K 10-Q · filed 2012-05-15 | $140.22K derived: sum of 2 quarters · filed 2013-03-18 | -$780.60K derived: sum of 3 quarters · filed 2013-03-18 | |||
| 2010-12-31 | -$685.40K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$1.61M derived: sum of 2 quarters · filed 2013-03-18 | -$5.78M 10-K · filed 2013-03-18 | |||
| 2010-09-30 | -$920.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | -$5.10M 10-Q · filed 2011-11-10 | ||||
| 2010-06-30 | -$4.18M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |